Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $56

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $54 to $56.

First FDA-Approved Treatment For Patients With Focal Segmental Glomerulosclerosis, A Rare Kidney Condition

https://www.fda.gov/drugs/drug-alerts-and-statements/first-fda-approved-treatment-patients-focal-segmental-glomerulosclerosis-rare-kidney-condition

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $53

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $48 to $53.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views

Dow Jones up 200 points, consumer discretionary shares rise 1.8%, Wells Fargo reports worse-than-expected earnings, Avanos Medical surges 69%.

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $56

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $47 to $56.

Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TVTX, BE, IONQ, SANA, RGTI, VACH, AOSL.

FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients

Travere says FILSPARI gains full FDA approval for FSGS, expanding treatment scope and showing strong proteinuria reduction in trials.

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $44

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $39 to $44.

Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $54

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $49 to $54.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 price target.

Ligand Pharmaceuticals Partner Travere Therapeutics Wins FDA Approval For First Drug Treating Rare Kidney Disease

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI®

Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times

Reported Earlier, Travere Therapeutics Wins FDA Approval Of FILSPARI For Focal Segmental Glomerulosclerosis Without Nephrotic Syndrome, Delivering 48% Proteinuria Reduction Vs 27% For Irbesar

FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndromeAdditional indication for FILSPARI expands total addressable population to more than

Trading Halt: Halted at 5:33:27 p.m. ET - Trading Halt: Halt News Pending